Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18491635 | 0.80 | CCNC (0.38) | KDM6BKDM4C | |
| SCHEMBL18491633 | 0.80 | CCNC (0.38) | KDM6BKDM4C | |
| SCHEMBL6288871 | 0.77 | TDP1 (0.41) | L3MBTL1TDP1 | |
| SCHEMBL6729852 | 0.77 | L3MBTL1 (0.36) | KDM6BKDM4CL3MBTL1TDP1 | |
| SCHEMBL994930 | 0.76 | LOXL2 (0.42) | KDM6BKDM4CL3MBTL1TDP1 | |
| SCHEMBL1044868 | 0.76 | GAA (0.37) | KDM6BKDM4CL3MBTL1TDP1 | |
| SCHEMBL18865581 | 0.73 | TDP1 (0.33) | KDM6BKDM4CL3MBTL1TDP1 | |
| SCHEMBL28498139 | 0.73 | CA12 (0.35) | L3MBTL1TDP1 | |
| SCHEMBL250163 | 0.72 | TDP1 (0.39) | KDM6BKDM4CL3MBTL1TDP1 | |
| SCHEMBL4204738 | 0.72 | CYP2D6 (0.35) | KDM6BKDM4CL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335672-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1789413-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006031852-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | KDM6B 3569/4885KDM4C 3707/4885L3MBTL1 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.